| 0.668 0.028 (4.38%) | 04-19 15:48 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.95 |
1-year : | 1.11 |
| Resists | First : | 0.81 |
Second : | 0.95 |
| Pivot price | 0.47 |
|||
| Supports | First : | 0.56 |
Second : | 0.4 |
| MAs | MA(5) : | 0.52 |
MA(20) : | 0.46 |
| MA(100) : | 0.53 |
MA(250) : | 0.64  |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 63.8 |
D(3) : | 71.3 |
| RSI | RSI(14): 70.5 |
|||
| 52-week | High : | 1.26 | Low : | 0.4 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TLSA ] has closed It is unclear right now based on current values. 162.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.59 - 0.59 | 0.59 - 0.59 |
| Low: | 0.5 - 0.51 | 0.51 - 0.51 |
| Close: | 0.51 - 0.51 | 0.51 - 0.52 |
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Fri, 19 Apr 2024
Tiziana Life Sciences' foralumab study highlighted in Neurology Today - Proactive Investors UK
Thu, 18 Apr 2024
Tiziana Life Sciences says foralumab shows promise in stabilizing certain types of MS - Proactive Investors USA
Thu, 11 Apr 2024
Tiziana Life Sciences to present new imaging data for lead asset at upcoming neurology conference - Proactive Investors Australia
Thu, 11 Apr 2024
Tiziana Showcases Foralumab's Neurotherapeutic Potential - TipRanks.com - TipRanks
Tue, 09 Jan 2024
TLSA: First Phase II SPMS Patient Dosed - Yahoo Finance
Fri, 13 Oct 2023
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 100 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 38 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 322 (K) |
| Shares Short P.Month | 303 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.12 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -44.7 % |
| Return on Equity (ttm) | -90.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -3.56 |
| PEG Ratio | 0 |
| Price to Book value | 4.92 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|